DELRAY BEACH, Fla., April 1, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (Nasdaq:PSID), a leader in next generation patient monitoring and diagnostics, announced today that it will host a WebEx of its iglucose™ diabetes management wireless solution for interested licensees, physicians, patients and investors on Wednesday, April 6, 2011 at 11:00 am ET. iglucose is a wireless communication device that connects to data-capable glucometers to automatically transmit blood glucose readings to a secure online database and designated third parties at pre-determined intervals, such as healthcare professionals, caregivers and insurance providers.
The demonstration will be available at:
To join the teleconference only, please dial 1-877-669-3239.
PositiveID's iglucose system ( www.iglucose.com ) is an innovative wireless communication solution that facilitates real-time diabetes management by automatically creating logs and journals, which the American Diabetes Association says are an important assessment of an individual's response to their diabetes care plan. iglucose provides next generation, real-time data to improve diabetes management by helping ensure patient compliance and data accuracy, and aiding in insurance reimbursement. This product has not been cleared for sale by the United States Food and Drug Administration.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit .
The PositiveID Corporation logo is available at
Statements about PositiveID's future expectations, including the ability of iglucose to provide next generation, real-time data to improve diabetes management by helping ensure patient compliance and data accuracy, and aiding in insurance reimbursement; the likelihood that iglucose will be cleared for sale by the United States Food and Drug Administration; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Allison Tomek 561-805-8000 firstname.lastname@example.org Dan Schustack CEOcast 212-732-4300 email@example.com